Related Experiment Videos
Peutz-Jeghers syndrome: risks of a hereditary condition
1Dept. of Internal Medicine II, University Hospital Rotterdam Dijkzigt, The Netherlands.
Insights
Peutz-Jeghers syndrome (PJS) carriers face risks from gastrointestinal polyps and an increased likelihood of developing various cancers. Genetic identification enables targeted surveillance for PJS patients and relatives.
Area of Science:
- Genetics
- Oncology
- Gastroenterology
Background:
- Peutz-Jeghers syndrome (PJS) is a rare autosomal-dominant disorder.
- Characterized by gastrointestinal hamartomatous polyposis and mucocutaneous melanin pigmentation.
- PJS is linked to mutations in the STK11 gene, a tumor suppressor.
Purpose of the Study:
- To review the clinical features of Peutz-Jeghers syndrome.
- To emphasize the cancer risks for PJS gene carriers.
- To highlight the need for surveillance protocols.
Main Methods:
- Literature review.
Main Results:
- PJS patients are at risk for surgical emergencies (e.g., intussusception) and bleeding due to polyps.
- Evidence suggests an association between PJS and both gastrointestinal and extra-intestinal tumors.
- Increased occurrence of rare malignancies (ovarian, cervical, testicular) indicates a general susceptibility.
Conclusions:
- PJS gene carriers face risks of polyp-related complications and increased cancer development.
- Genetic identification of carriers is crucial for developing surveillance and screening protocols.
- Proactive management is essential for PJS patients and their families.
Background:
Peutz-Jeghers syndrome (PJS) is a rare autosomal-dominant disorder characterized by hamartomatous polyposis of the gastrointestinal tract and melanin pigmentation of the skin and mucous membranes. We review the clinical features of PJS with special emphasis on the risks for its gene carriers.
Methods:
Review of the literature.
Results:
Risks imposed by the presence of polyps in PJS patients include surgical emergencies like small bowel intussusception, and chronic or acute bleeding from the polyps. As the polyps in PJS are hamartomas, the disease had in the past always been thought not to have malignant potential. However, more and more reports suggest an association of PJS with both gastrointestinal and non-gastrointestinal tumours. Whether these malignancies originate from the polyps is not clear, but the frequent occurrence of some rare extra-intestinal malignancies such as tumours of the ovary (sex cord tumours with annular tubules), cervix (adenoma malignum) and testis (Sertoli cell tumours) indicates a general susceptibility for the development of malignancies. The PJS gene, which was recently identified to encode for the serine threonine kinase STK11, is therefore thought to act as a tumour-suppressor gene.
Conclusions:
PJS gene carriers not only run risks of polyp-induced gastrointestinal complications, but also are at increased risk of developing cancer, both within and outside the gastrointestinal tract. As genetic identification of asymptomatic gene carriers in this relatively rare disorder becomes possible, surveillance and screening protocols need to be developed for PJS patients and their relatives.